Zhigang Wang

Dr. Zhigang Wang

Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2022 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
WKWannee Kantasiripitak
Wannee Kantasiripitak
AOAn Outtier
An Outtier
SWSebastian Georg Wicha
Sebastian Georg Wicha
AKAlexander Kensert
Alexander Kensert
Zhigang WangZhigang Wang
Zhigang Wang
Erwin DreesenErwin Dreesen
Erwin Dreesen
Infliximab dosage de‐escalation without prior knowledge of drug concentrations may put patients at risk for underexposure and trigger the loss of response. A single‐model approach for model‐informed precision dosing during infliximab maintenance therapy has proven its clinical benefit in patients with inflammatory bowel diseases. We evaluated the predictive performances of two multi‐model approaches, a model selection algorithm and a model averaging algorithm, using 18 published population pharmacokinetic models of infliximab for guiding dosage de‐escalation. Data of 54 patients with Crohn’s disease and ulcerative colitis who underwent infliximab dosage de‐escalation after an earlier escalation were used. A priori prediction (based solely on covariate data) and maximum a posteriori prediction (based on covariate data and trough concentrations) were compared using accuracy and precision metrics and the classification accuracy at the trough concentration target of 5.0 mg/L. A priori prediction was inaccurate and imprecise, with the lowest classification accuracies irrespective of the approach (median 59%, interquartile range 59%–63%). Using the maximum a posteriori prediction, the model averaging algorithm had systematically better predictive performance than the model selection algorithm or the single‐model approach with any model, regardless of the number of concentration data. Only a single trough concentration (preferably at the point of care) sufficed for accurate and precise prediction. Predictive performance of both single‐ and multi‐model approaches was robust to the lack of covariate data. Model averaging using four models demonstrated similar predictive performance with a five‐fold shorter computation time. This model averaging algorithm was implemented in the TDMx software tool to guide infliximab dosage de‐escalation in the forthcoming prospective MODIFI study (NCT04982172).

25 February 2017 in FEBS Letters
Verified
Journal Article
Open access
PDF file
CLCheng Li
Cheng Li
LZLufeng Zheng
Lufeng Zheng
YXYu Xin
Yu Xin
ZTZhoulin Tan
Zhoulin Tan
YZYan Zhang
Yan Zhang
TXTao Xi
Tao Xi
The competing endogenousRNAnetwork (ceRNET) is involved in tumorigenesis and has become a hot spot of research. The ceRNETbetweenCYP4Z1 and the pseudogeneCYP4Z2P promotes angiogenesis and mediates tamoxifen resistance in breast cancer. Nevertheless, the effects of this ceRNETon cell apoptosis and related mechanisms remain unclear. In the present study, we found that downregulation ofCYP4Z1 or theCYP4Z2P 3′‐UTRpromotes cell apoptosis, mirroring the functions of human telomerase reverse transcriptase (hTERT). Furthermore, the ceRNETbetweenCYP4Z1 and pseudogeneCYP4Z2P modulateshTERTexpression by operating as a sub‐ceRNETforhTERT. Our data demonstrate that the ceRNETbetweenCYP4Z1 and pseudogeneCYP4Z2P acts as a sub‐ceRNETforhTERTand, thus, inhibits breast cancer apoptosis.

1 July 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
Zhigang WangZhigang Wang
Zhigang Wang
BVBram Verstockt
Bram Verstockt
JSJoão Sabino
João Sabino
SVSéverine Vermeire
Séverine Vermeire
MFMarc Ferrante
Marc Ferrante
Erwin DreesenErwin Dreesen
Erwin Dreesen

17 April 2024 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
DADahham Alsoud
Dahham Alsoud
Dirk Jan Alie Roelof MoesDirk Jan Alie Roelof Moes
Dirk Jan Alie Roelof Moes
Zhigang WangZhigang Wang
Zhigang Wang
RSRani Soenen
Rani Soenen
ZLZohra Layegh
Zohra Layegh
Erwin DreesenErwin Dreesen
Erwin Dreesen
Background: Infliximab, an anti–tumor necrosis factor monoclonal antibody, has revolutionized the pharmacological management of immune-mediated inflammatory diseases (IMIDs). This position statement critically reviews and examines existing data on therapeutic drug monitoring (TDM) of infliximab in patients with IMIDs. It provides a practical guide on implementing TDM in current clinical practices and outlines priority areas for future research. Methods: The endorsing TDM of Biologics and Pharmacometrics Committees of the International Association of TDM and Clinical Toxicology collaborated to create this position statement. Results: Accumulating data support the evidence for TDM of infliximab in the treatment of inflammatory bowel diseases, with limited investigation in other IMIDs. A universal approach to TDM may not fully realize the benefits of improving therapeutic outcomes. Patients at risk for increased infliximab clearance, particularly with a proactive strategy, stand to gain the most from TDM. Personalized exposure targets based on therapeutic goals, patient phenotype, and infliximab administration route are recommended. Rapid assays and home sampling strategies offer flexibility for point-of-care TDM. Ongoing studies on model-informed precision dosing in inflammatory bowel disease will help assess the additional value of precision dosing software tools. Patient education and empowerment, and electronic health record–integrated TDM solutions will facilitate routine TDM implementation. Although optimization of therapeutic effectiveness is a primary focus, the cost-reducing potential of TDM also merits consideration. Conclusions: Successful implementation of TDM for infliximab necessitates interdisciplinary collaboration among clinicians, hospital pharmacists, and (quantitative) clinical pharmacologists to ensure an efficient research trajectory.

2 December 2021 in Expert Review of Clinical Pharmacology
Verified
Journal Article
Closed access
WKWannee Kantasiripitak
Wannee Kantasiripitak
Zhigang WangZhigang Wang
Zhigang Wang
ISIsabel Spriet
Isabel Spriet
MFMarc Ferrante
Marc Ferrante
Erwin DreesenErwin Dreesen
Erwin Dreesen
Less than 50% of patients with inflammatory bowel diseases (IBD) receiving monoclonal antibody (mAb) therapy achieve endoscopic remission. Poor outcomes may indicate a need for dose optimization. D...

12 January 2023 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
Zhigang WangZhigang Wang
Zhigang Wang
BVBram Verstockt
Bram Verstockt
JSJoão Sabino
João Sabino
MFMarc Ferrante
Marc Ferrante
SVSéverine Vermeire
Séverine Vermeire
Erwin DreesenErwin Dreesen
Erwin Dreesen